BD Advances Iliac Artery Treatment Across the European Union 

BD (Becton, Dickinson and Company), a leading global medical technology company, announced that it has obtained CE Marking for the Revello Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries. This advancement arrives as lower‑extremity peripheral artery disease (PAD), including iliac artery disease, is a key component that drives a substantial disability burden across the EU’s ageing population. 

The Revello Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac arteries. Worldwide president, BD Interventional, Rima Alameddine, said, the CE Marking of the Revello Stent is a significant advancement towards helping physicians treat complex iliac artery disease. 

It was built to raise the standard of iliac artery revascularisation to expand the growing BD peripheral vascular portfolio and reinforce the company’s commitment to deliver clinically relevant innovation for physicians treating complex PAD across the EU and EEA countries. 

According to Towards Healthcare, the Iliac Stents Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.23 billion in 2026 to approximately USD 2.22 billion by 2035, representing a compound annual growth rate (CAGR) of 6.8% from 2026 to 2035. Growth is driven by technological advancement in stent design and the rising demand for minimally invasive procedures, with stringent regulatory approval ensuring the safety and efficacy of stent devices. 

Tri-axial delivery system designed for controlled deployment and accurate placement. The system includes an atraumatic tip for smooth insertion, a stability sheath for smooth and precise delivery, and a thumbwheel that provides intuitive control and precise adjustments during deployment. Revello Stent offers more diameters on a lower profile platform compared to self-expanding iliac artery stents in the European market. This helps to reduce the risk of access site complications. 

EU Availability 

The physicians discussed its potential impact on iliac interventions when the Revello Stent was introduced at the LINC 2026 congress in Germany. Dr Michael Lichtenberg, a physician and Angiologist highlights the ongoing AGILITY clinical trial, which is evaluating the device’s performance in patients with PAD. 

Dr Sean Lyden, chairman of the Department of Vascular Surgery at Cleveland Clinic in Cleveland, Ohio, and Dr Lichtenberg, European principal, said this trial is a prospective, multi-centre study led by a global principal investigator. 

A recent report by Towards Healthcare highlights that the Iliac Stents Market is witnessing growth due to a shift towards self-expandable stents, drug-eluting, and covered stents in complex lesions, and outpatient and day-care endovascular procedures, with a focus on innovation and integration of advanced technologies to meet growing demands for effective vascular treatment. 

North America is the largest market, while the Asia-Pacific is expected to be the fastest-growing region. The market is characterised by a low level of M&A activities and heightened regulatory scrutiny, with the FDA actively implementing more rigorous guidelines.